Uric Acid Study in Healthy Male Volunteers
Study identifier:D5130C00050
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Double-Blind, Two-Period Crossover Study to Assess the Effect of AZD6140 on Uric Acid Levels in Healthy Male Volunteers
Medical condition
Gout, Coronary artery disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6140, Placebo to match AZD6140
Sex
Male
Actual Enrollment
24
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 May 2008
Primary Completion Date: 01 Jul 2008
Study Completion Date: 01 Jul 2008
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD6140 Oral tablets taken bid for 5 days |
| Placebo Comparator: 2 | Drug: Placebo to match AZD6140 Oral tablets taken bid for 5 days |
Contacts
Investigators
Principal Investigator
Kathleen Butler
AstraZeneca
